TrialCNS drugs2020

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.

Tjalf Ziemssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.